EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population Prevalence, Penetrance, and Mortality for Genetically Confirmed MODY

Luke N Sharp iD, Kevin Colclough, Jacques Murray Leech iD, Stuart J Cannon iD, Thomas W Laver iD, Andrew T Hattersley iD, Michael N Weedon iD, Kashyap A Patel iD

The Journal of Clinical Endocrinology & Metabolism · 22.04.2026 · 111 (5) · e1388-e1395

DOI: 10.1210/clinem/dgaf599 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 01.11.2025. Verfasst von Luke N Sharp und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter EX4 4QJ, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Penetrance. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Biobank, Diabetes UK, MRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Diagnosing maturity-onset diabetes of the young (MODY) is clinically important for treatment and prognosis. However, phenotype-based studies of MODY are prone to ascertainment bias, limiting accurate estimates of its population prevalence and phenotypic spectrum.

Objective

To apply a genotype-first approach to determine the population prevalence, penetrance, and all-cause mortality associated with MODY.

Methods

We analyzed exome sequencing and clinical data from 454 275 UK Biobank participants to identify pathogenic variants in 10 established MODY genes. We assessed variant prevalence, age-dependent diabetes penetrance, and all-cause mortality by genetic etiology over a mean follow-up of 13.4 years.

Results

Pathogenic MODY variants were present in 1 in 1052 individuals and accounted for 1.48% of diabetes cases diagnosed before age 40. GCK variants were the most frequent (1 in 2787), demonstrating high penetrance (mean HbA1c 8.8 mmol/mol higher; 94.5% with prediabetes or diabetes) but no significant association with all-cause mortality (P = .09). Variants in other MODY genes showed lower penetrance, with 12% of carriers developing diabetes by age 40 and 31.6% by age 60 and showed no increase in all-cause mortality (P = .89). Penetrance varied by genetic etiology, with HNF1A showing the highest penetrance and PDX1, NEUROD1, and RFX6 the lowest. Parental history of diabetes and polygenic risk for type 2 diabetes were important modifiers of penetrance (hazard ratios 2.54 and 1.52, respectively; P < 3.9 × 10−3).

Conclusion

This large-scale genotype-first study provides novel insights into MODY in the population. These findings have broad implications for genetic counseling, personalized treatment strategies, and healthcare resource allocation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2PenetranceHumansMaleFemaleAdultMiddle AgedPrevalenceUnited KingdomAgedFollow-Up StudiesExome SequencingYoung AdultGenetic Predisposition to DiseaseGenotype

Stichwörter der Autor:innen

MODYdiabetesgeneticsmonogenic diabetespenetrance

Autor:innen und Institutionen

  • Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter EX4 4QJ, UK.
  • Exeter Genomic Laboratory, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.

ORCID-Profile: Luke N Sharp, Jacques Murray Leech, Stuart J Cannon, Thomas W Laver, Andrew T Hattersley, Michael N Weedon, Kashyap A Patel

Förderung

  • UK Biobank
  • Diabetes UK
  • MRC
  • Wellcome Trust
  • National Institute for Health Research
  • Exeter Biomedical Research Centre
  • Academy of Medical Sciences
  • Government Department of Science Innovation and Technology

Zitieren

APA

Sharp, L. N., Colclough, K., Murray Leech, J., Cannon, S. J., Laver, T. W., Hattersley, A. T., Weedon, M. N., & Patel, K. A. (2026). Population Prevalence, Penetrance, and Mortality for Genetically Confirmed MODY. The Journal of Clinical Endocrinology & Metabolism, 111(5), e1388-e1395. https://doi.org/10.1210/clinem/dgaf599

Vancouver

Sharp LN, Colclough K, Murray Leech J, Cannon SJ, Laver TW, Hattersley AT, et al. Population Prevalence, Penetrance, and Mortality for Genetically Confirmed MODY. The Journal of Clinical Endocrinology & Metabolism. 2026;111(5):e1388-e1395. doi:10.1210/clinem/dgaf599

BibTeX
@article{Sharp2026,
  author = {Sharp, Luke N and Colclough, Kevin and Murray Leech, Jacques and Cannon, Stuart J and Laver, Thomas W and Hattersley, Andrew T and Weedon, Michael N and Patel, Kashyap A},
  title = {Population Prevalence, Penetrance, and Mortality for Genetically Confirmed MODY},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {5},
  pages = {e1388--e1395},
  doi = {10.1210/clinem/dgaf599}
}
Kostenlos starten →